Kiromic Biopharma Inc (PK:KRBP)

Business Focus: Bio Therapeutic Drugs

Apr 02, 2024 08:18 am ET

Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing tumor stabilization in the third patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies.

Mar 19, 2024 08:08 am ET

Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing primary lung tumor stabilization and the complete disappearance of brain metastases in the second patient in the Company’s Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC).

Mar 08, 2024 08:35 am ET

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held March 7th are now available for online viewing. This event was sponsored by Zacks...

Mar 05, 2024 08:35 am ET

Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held March 7th. This event is sponsored by Zacks Small-Cap Research. Individual investors,...

Mar 01, 2024 08:08 am ET

Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Virginia Oncology Associates, PC (Norfolk, Virginia) has been activated as the second clinical trial site in the Phase 1 Deltacel-01 trial evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with non-small cell lung cancer (NSCLC).

Feb 28, 2024 06:30 pm ET

Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Chief Executive Officer Pietro Bersani, Chief Financial Officer Brian Hungerford and Chief Scientific Officer and Interim Operations Officer Leonardo Mirandola, Ph.D., will participate in the OTC Markets’ Life Science Investor Forum in a Fireside Chat format, hosted by VirtualInvestorConferences.com, on March 7th, 2024.

Feb 28, 2024 04:09 pm ET

Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th

Feb 14, 2024 08:08 am ET

Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces continued encouraging clinical findings from the most recent follow-up visit of the first patient enrolled in Deltacel-01, the Company’s Phase 1 clinical trial evaluating Deltacel™ for the treatment of stage 4 metastatic non-small cell lung cancer (NSCLC). After stable disease and preliminary progression-free survival of one and a half months were reported six weeks post-treatment, the two-month follow-up PET/CT scan revealed that the patient’s tumor size was reduced by 6.6%, and no new disease sites

Jan 29, 2024 07:47 am ET

Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable early efficacy results from the first patient enrolled in the Phase 1 Deltacel-01 clinical trial with Deltacel™ for treating stage 4 metastatic non-small cell lung cancer (NSCLC).

Jan 05, 2024 08:08 am ET

Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, reports favorable safety and tolerability from the first patient 23 days after Deltacel™ infusion in the Phase 1 clinical trial for treatment of stage 4 metastatic non-small cell lung cancer (NSCLC) at Beverly Hills Cancer Center, located in Beverly Hills, California, USA. Specifically, laboratory test results and

Dec 14, 2023 08:17 am ET

Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces that the first patient has initiated treatment at the Beverly Hills Cancer Center (BHCC) in the Company’s Deltacel-01 clinical trial. This Phase 1 study is evaluating Deltacel™ for the treatment of stage 4 metastatic non-small cell lung cancer (NSCLC).

Sep 13, 2023 04:35 pm ET

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14

Kiromic BioPharma (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces that on September 12, 2023 it received formal notice from the NASDAQ Stock Market that the Company’s common stock has been suspended from trading on the Nasdaq Capital Market effective September 14, 2023, due to failure to demonstrate compliance with Listing Rule 5550(b)(1).

Jul 24, 2023 03:00 pm ET

Kiromic BioPharma Welcomes Two New Directors to its Board

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the appointments of Pamela Misajon and Michael Catlin to its Board of Directors. Their regulatory and finance experience enhances Kiromic’s governance and re-establishes the Company’s five-member Board of Directors.

May 01, 2023 08:08 am ET

Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, today announces that the U.S. Food and Drug Administration (FDA) has authorized the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial to evaluate Deltacel (KB-GDT-01) for patients with non-small cell lung cancer (NSCLC).

Apr 03, 2023 08:08 am ET

Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial to evaluate KB-GDT-01, or Deltacel, in combination with an anti-tumor therapy for the treatment of non-small cell lung cancer (NSCLC).

Mar 10, 2023 04:30 pm ET

Kiromic BioPharma Announces Reverse Stock Split

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 effective as of 4:01 p.m. Eastern Time today, March 10, 2023. Kiromic common stock will begin trading on a split-adjusted basis when the market opens on March 13, 2023 under the existing trading symbol KRBP. As

Feb 28, 2023 08:08 am ET

Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces favorable safety results from the histopathology evaluation of a preclinical study of the pharmacology of KB-GDT-01 (trademark: Deltacel™) administered alone and in combination with a non-biological anti-tumor therapy in mice.

Feb 25, 2023 08:11 pm ET

Lifshitz Law PLLC Announces Investigations of FMIA, SUMO, KRBP, and HYRE

First Miami Bancorp, Inc. (OTC: FMIA) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of FMIA to United Community Banks, Inc. for 40.2685 shares of United common stock for...

Feb 23, 2023 12:17 pm ET

Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote “FOR” All Proxy Proposals

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces that Institutional Shareholder Services (ISS) and Glass Lewis & Co. (Glass Lewis), two leading independent proxy advisory firms, have issued recommendations that Kiromic stockholders vote FOR all three proposals at the Company’s Special Meeting of Stockholders being held March 7, 2023.

Feb 16, 2023 08:08 am ET

Kiromic BioPharma CEO Issues Letter to Stockholders

Nov 08, 2022 08:30 am ET

SHAREHOLDER ALERT: Kiromic Biopharma, Inc. (KRBP) Officers and Directors Under Investigation for Possible False Statements About Its Commercial Prospects

SAN FRANCISCO, Nov. 8, 2022 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Kiromic Biopharma, Inc. (NASDAQ: KRBP) relating to possible false and misleading statements to investors concerning commercial prospects for the company's immunotherapy medications.

Oct 27, 2022 08:48 am ET

Kiromic BioPharma Arranges Up to $10 Million Financing

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces it entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD, a partnership managed by Yorkville Advisors Global LP, a global investment manager, to sell up to $8 million of the Company’s stock at any time during the 24 months following the date of the SEPA, subject to the

Oct 06, 2022 08:08 am ET

Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy

The purpose of the Pre-IND meeting request was to seek alignment with and to obtain FDA guidance on Kiromic’s proposed development strategy about the chemistry, manufacturing, and controls (CMC), nonclinical studies, and clinical study plan for Deltacel™/KB-GDT for treating subjects with Non-Small Cell Lung Cancer (NSCLC). Kiromic will leverage this FDA Pre-IND written confirmatory feedback and recommendations into a robust IND submission package for a projected clinical trial launch in Q1 2023.

Oct 04, 2022 12:29 pm ET

Gainey McKenna & Egleston Filed The First Class Action Lawsuit Against Kiromic BioPharma, Inc. (KRBP); The Class Period Has Been Enlarged from June 25, 2021 to February 2, 2022; And The Motion Deadlin

Gainey McKenna & Egleston filed the first class action lawsuit against Kiromic BioPharma, Inc. (“Kiromic” or the “Company”) (NASDAQ: KRBP) and against certain officers and directors of the Company regarding the allegations below. The proposed class...

Oct 04, 2022 11:36 am ET

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, Oct. 4, 2022 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ: KRBP) for violations of the federal securities laws.

Oct 04, 2022 05:45 am ET

KRBP ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2022 in the Class Action Filed on Behalf of Kiromic BioPharma, Inc. Shareholders

NEW YORK, Oct. 4, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP) alleging that the Company violated federal securities laws.

Oct 03, 2022 06:15 pm ET

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. With Losses of $75,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 3, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ:KRBP) for violations of the federal securities laws.

Oct 03, 2022 11:00 am ET

Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kiromic BioPharma, Inc. (KRBP) Investors of Class Action and to Actively Participate

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Kiromic BioPharma, Inc. (“Kiromic” or the “Company”) (NASDAQ: KRBP) and certain of its officers, on behalf of a class consisting of all persons and entities that purchased or otherwise acquired Kiromic: (1) common stock pursuant and/or traceable to the Offering Documents (defined below) and/or (2) securities between June 25, 2021, and August 13, 2021, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:

Oct 03, 2022 10:45 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma Inc. -KRBP

NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Oct 03, 2022 09:15 am ET

Final Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed against Kiromic BioPharma, Inc. (KRBP)

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Kiromic BioPharma, Inc....

Oct 03, 2022 05:45 am ET

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Kiromic Investors of a Lead Plaintiff Deadline of October 4, 2022

NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Attention Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP) shareholders:

Oct 02, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coinbase, Carvana, Kiromic, and LifeStance and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Coinbase Global, Inc. (NASDAQ: COIN), Carvana Co. (NYSE: CVNA), Kiromic...

Oct 02, 2022 12:01 pm ET

KRBP Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Kiromic BioPharma, Inc. of Deadline in Securities Fraud Class Action Lawsuit

RADNOR, Pa., Oct. 2, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP). The action charges Kiromic with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Kiromic's materially misleading statements and omissions to the public, Kiromic investors have suffered significant losses.

Oct 02, 2022 10:16 am ET

KRBP 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys Before Oct. 4th Deadline in Securi

Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now. Class Period: June 25, 2021 – Aug. 13, 2021Lead Plaintiff Deadline: Oct. 4, 2022Visit:...

Sep 30, 2022 09:00 pm ET

KIROMIC DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Kiromic BioPharma, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Kiromic BioPharma, Inc. (“Kiromic” or the “Company”) (NASDAQ: KRBP) in the United States district Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Kiromic securities between June 25, 2021 and August 13, 2021, both dates inclusive, or pursuant to the Company’s July 2, 2021 IPO (the “Class Period”). Investors have until October 4, 2022 to apply to the Court to be appointed as lea

Sep 30, 2022 03:07 pm ET

KRBP TUESDAY DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors With Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action - KRBP

NEW YORK, Sept. 30, 2022 /PRNewswire/ --

Sep 30, 2022 05:45 am ET

KRBP SHAREHOLDER ALERT: Jakubowitz Law Reminds Kiromic Shareholders of a Lead Plaintiff Deadline of October 4, 2022

NEW YORK, Sept. 30, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP).

Sep 29, 2022 05:45 am ET

KRBP LAWSUIT ALERT: Levi & Korsinsky Notifies Kiromic BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Sept. 29, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) of a class action securities lawsuit.

Sep 28, 2022 07:58 pm ET

KRBP DEADLINE NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important October 4 Deadline in Securities Class Action – KRBP

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kiromic BioPharma, Inc. (NASDAQ: KRBP): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public...

Sep 28, 2022 07:38 pm ET

KRBP DEADLINE NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important October 4 Deadline in Securities Class Action – KRBP

Sep 28, 2022 05:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Kiromic BioPharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 4, 2022 - (NASDAQ: KRBP)

NEW YORK, Sept. 28, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kiromic BioPharma, Inc..

Sep 27, 2022 08:30 pm ET

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $50,000 to Contact

NEW YORK, NY / ACCESSWIRE / September 27, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ:KRBP) for violations of the federal securities laws.

Sep 27, 2022 06:07 pm ET

Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed against Kiromic BioPharma, Inc.

Sep 27, 2022 03:50 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma Inc. -KRBP

Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma Inc. (“Kiromic” or the “Company”) (NASDAQ: KRBP). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....

Sep 27, 2022 02:10 pm ET

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys Before Oct. 4th Deadline in Securities Class Action

Sep 26, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kiromic, LifeStance, MINISO, and Co-Dx and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP), LifeStance Health Group, Inc. (NASDAQ:...

Sep 24, 2022 04:04 pm ET

KRBP DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP - Important October 4, 2022 Deadline Reminder for Kiromic BioPharma, Inc.

RADNOR, Pa., Sept. 24, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP). The action charges Kiromic with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Kiromic's materially misleading statements and omissions to the public, Kiromic investors have suffered significant losses.

Sep 23, 2022 05:45 am ET

KRBP SHAREHOLDER ALERT: Jakubowitz Law Reminds Kiromic Shareholders of a Lead Plaintiff Deadline of October 4, 2022

NEW YORK, Sept. 23, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP).

Sep 22, 2022 01:04 pm ET

KRBP 12-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys Before Oct. 4th Deadline in Secur

Sep 22, 2022 11:16 am ET

COIN, KRBP & TUYA Class Actions: Bronstein, Gewirtz & Grossman, LLC, A Top Class Action Firm, Reminds Investors to Contact the Firm and Actively Participate

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...

Sep 22, 2022 05:45 am ET

KRBP LAWSUIT ALERT: Levi & Korsinsky Notifies Kiromic BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Sept. 22, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) of a class action securities lawsuit.

Sep 21, 2022 04:02 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma Inc. -KRBP

Sep 21, 2022 02:17 pm ET

Kiromic BioPharma, Inc. Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds KRBP Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf

The law firm of Kessler Topaz Meltzer & Check, LLP (

Sep 21, 2022 05:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Kiromic BioPharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 4, 2022 - (NASDAQ: KRBP)

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kiromic BioPharma, Inc..

Sep 20, 2022 05:45 am ET

KRBP ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2022 in the Class Action Filed on Behalf of Kiromic BioPharma, Inc. Shareholders

NEW YORK, Sept. 20, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP) alleging that the Company violated federal securities laws.

Sep 19, 2022 04:52 pm ET

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important October 4 Deadline in Securities Class Action – KRBP

Sep 19, 2022 12:41 pm ET

KRBP Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of October 4, 2022 Deadline in Securities Fraud Class Action Lawsuit

Sep 19, 2022 05:45 am ET

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Kiromic Investors of a Lead Plaintiff Deadline of October 4, 2022

NEW YORK, Sept. 19, 2022 /PRNewswire/ -- Attention Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP) shareholders:

Sep 17, 2022 12:08 pm ET

KRBP CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Pending

Sep 16, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Carvana, Kiromic, Tuya, and LifeStance and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Carvana Co. (NYSE: CVNA), Kiromic BioPharma, Inc. (NASDAQ: KRBP), Tuya, Inc....

Sep 16, 2022 02:58 pm ET

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - KRBP

NEW YORK, Sept. 16, 2022 /PRNewswire/ --

Sep 16, 2022 01:37 pm ET

KRBP DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Kiromic BioPharma, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to

RADNOR, Pa., Sept. 16, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP). The action charges Kiromic with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Kiromic's materially misleading statements and omissions to the public, Kiromic investors have suffered significant losses.

Sep 16, 2022 05:45 am ET

KRBP SHAREHOLDER ALERT: Jakubowitz Law Reminds Kiromic Shareholders of a Lead Plaintiff Deadline of October 4, 2022

NEW YORK, Sept. 16, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP).

Sep 15, 2022 05:45 am ET

KRBP LAWSUIT ALERT: Levi & Korsinsky Notifies Kiromic BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Sept. 15, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) of a class action securities lawsuit.

Sep 14, 2022 09:39 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma Inc. -KRBP

Sep 14, 2022 02:33 pm ET

Gainey McKenna & Egleston Filed A Class Action Lawsuit Against Kiromic BioPharma, Inc. (KRBP)

Gainey McKenna & Egleston is the only firm that filed a class action lawsuit against Kiromic BioPharma, Inc. (“Kiromic” or the “Company”) (NASDAQ: KRBP) and against certain officers and directors of the Company regarding the allegations below. The...

Sep 14, 2022 05:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Kiromic BioPharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 4, 2022 - (NASDAQ: KRBP)

NEW YORK, Sept. 14, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kiromic BioPharma, Inc..

Sep 13, 2022 04:12 pm ET

ROSEN, A TOP RANKED FIRM, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – KRBP

Sep 13, 2022 05:45 am ET

KRBP ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2022 in the Class Action Filed on Behalf of Kiromic BioPharma, Inc. Shareholders

NEW YORK, Sept. 13, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP) alleging that the Company violated federal securities laws.

Sep 12, 2022 10:39 am ET

KRBP INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed

Sep 12, 2022 05:45 am ET

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Kiromic Investors of a Lead Plaintiff Deadline of October 4, 2022

NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP) shareholders:

Sep 11, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kiromic, Tuya, LifeStance, and MINISO and Encourages Investors to Contact the Firm

Sep 11, 2022 07:31 pm ET

Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed against Kiromic BioPharma, Inc.

Sep 09, 2022 07:15 pm ET

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – KRBP

Sep 09, 2022 05:45 am ET

KRBP SHAREHOLDER ALERT: Jakubowitz Law Reminds Kiromic Shareholders of a Lead Plaintiff Deadline of October 4, 2022

NEW YORK, Sept. 9, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP).

Sep 08, 2022 10:21 pm ET

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - KRBP

NEW YORK, Sept. 8, 2022 /PRNewswire/ --

Sep 08, 2022 05:45 am ET

KRBP LAWSUIT ALERT: Levi & Korsinsky Notifies Kiromic BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Sept. 8, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) of a class action securities lawsuit.

Sep 07, 2022 08:52 am ET

Important Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Kiromic BioPharma, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit

RADNOR, Pa., Sept. 7, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP). The action charges Kiromic with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Kiromic's materially misleading statements and omissions to the public, Kiromic investors have suffered significant losses.

Sep 07, 2022 05:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Kiromic BioPharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 4, 2022 - (NASDAQ: KRBP)

NEW YORK, Sept. 7, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kiromic BioPharma, Inc..

Sep 06, 2022 09:28 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Weber, Coinbase, Carvana, and Kiromic and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Weber, Inc. (NYSE: WEBR), Coinbase Global, Inc. (NASDAQ: COIN), Carvana Co....

Sep 06, 2022 03:56 pm ET

KRBP DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Pending

Sep 06, 2022 03:17 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma Inc. -KRBP

Sep 06, 2022 03:15 pm ET

ROSEN, A LEADING LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - KRBP

NEW YORK, Sept. 6, 2022 /PRNewswire/ --

Sep 06, 2022 01:00 pm ET

KRBP ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2022 in the Class Action Filed on Behalf of Kiromic BioPharma, Inc. Shareholders

NEW YORK, Sept. 6, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP) alleging that the Company violated federal securities laws.

Sep 04, 2022 12:00 pm ET

ROSEN, A TOP RANKED LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – KRBP

Sep 03, 2022 09:44 am ET

KRBP EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit filed against Kiromic BioPharma, Inc.

Sep 02, 2022 11:12 am ET

COIN, KRBP & TUYA Class Actions: Bronstein, Gewirtz & Grossman, LLC, A Leading Class Action Firm, Reminds Investors to Contact the Firm and Actively Participate

Sep 02, 2022 05:45 am ET

KRBP SHAREHOLDER ALERT: Jakubowitz Law Reminds Kiromic Shareholders of a Lead Plaintiff Deadline of October 4, 2022

NEW YORK, Sept. 2, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP).

Sep 01, 2022 05:45 am ET

KRBP LAWSUIT ALERT: Levi & Korsinsky Notifies Kiromic BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Sept. 1, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) of a class action securities lawsuit.

Aug 31, 2022 09:41 pm ET

ROSEN, A LEADING LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - KRBP

NEW YORK, Aug. 31, 2022 /PRNewswire/ --

Aug 31, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Weber, Coinbase, Carvana, and Kiromic and Encourages Investors to Contact the Firm

Aug 31, 2022 05:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Kiromic BioPharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 4, 2022 - (NASDAQ: KRBP)

NEW YORK, Aug 31, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kiromic BioPharma, Inc.

Aug 30, 2022 02:44 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma Inc. - KRBP

Aug 30, 2022 05:45 am ET

KRBP ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2022 in the Class Action Filed on Behalf of Kiromic BioPharma, Inc. Shareholders

NEW YORK, Aug. 30, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP) alleging that the Company violated federal securities laws.

Aug 29, 2022 05:05 pm ET

INVESTOR NOTIFICATION: Kessler Topaz Meltzer & Check, LLP Announces Lead Plaintiff Deadline on October 4, 2022 in Securities Fraud Class Action Lawsuit Filed against Kiromic BioPharma, Inc.

RADNOR, Pa., Aug. 29, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP). The action charges Kiromic with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Kiromic's materially misleading statements and omissions to the public, Kiromic investors have suffered significant losses.

Aug 29, 2022 02:15 pm ET

KRBP CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed

Aug 29, 2022 01:48 pm ET

ROSEN, A TOP RANKED FIRM, Encourages Kiromic BioPharma, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – KRBP

Aug 29, 2022 05:45 am ET

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Kiromic Investors of a Lead Plaintiff Deadline of October 4, 2022

NEW YORK, Aug. 29, 2022 /PRNewswire/ -- Attention Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP) shareholders:

Aug 26, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kiromic, Tuya, LifeStance, and MINISO and Encourages Investors to Contact the Firm

Aug 26, 2022 08:00 pm ET

Gainey McKenna & Egleston Filed A Class Action Lawsuit Against Kiromic BioPharma, Inc. (KRBP)

Aug 26, 2022 05:30 pm ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $50,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 26, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ:KRBP) for violations of the federal securities laws.

Aug 26, 2022 08:40 am ET

Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Kiromic BioPharma, Inc. of Securities Class Action Lawsuit and Urges Investors with Significant Losses to Contact the Firm

Aug 26, 2022 05:45 am ET

KRBP SHAREHOLDER ALERT: Jakubowitz Law Reminds Kiromic Shareholders of a Lead Plaintiff Deadline of October 4, 2022

NEW YORK, Aug. 26, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP).

Aug 25, 2022 05:45 am ET

KRBP LAWSUIT ALERT: Levi & Korsinsky Notifies Kiromic BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Aug. 25, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) of a class action securities lawsuit.

Aug 24, 2022 06:15 pm ET

ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KRBP

NEW YORK, Aug. 24, 2022 /PRNewswire/ --

Aug 24, 2022 12:56 pm ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Kiromic BioPharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 4, 2022 - (NASDAQ: KRBP)

NEW YORK, Aug. 24, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kiromic BioPharma, Inc..

Aug 23, 2022 05:45 am ET

KRBP ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2022 in the Class Action Filed on Behalf of Kiromic BioPharma, Inc. Shareholders

NEW YORK, Aug. 23, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP) alleging that the Company violated federal securities laws.

Aug 22, 2022 05:57 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma Inc. -KRBP

Aug 22, 2022 04:21 pm ET

Kiromic Biopharma, Inc. Shareholder News: Robbins LLP is Investigating Kiromic Biopharma, Inc. (KRBP) on Behalf of Shareholders

Shareholder rights law firm Robbins LLP is investigating Kiromic Biopharma, Inc. (NASDAQ: KRBP) and its officers and directors to determine whether they breached fiduciary duties or violated securities laws in connection with the Company's July 2021 initial public offering ("IPO") by failing to disclose the FDA had placed a clinical

Aug 22, 2022 02:41 pm ET

KRBP LAWSUIT: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed

Aug 22, 2022 05:45 am ET

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Kiromic Investors of a Lead Plaintiff Deadline of October 4, 2022

NEW YORK, Aug. 22, 2022 /PRNewswire/ -- Attention Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP) shareholders:

Aug 22, 2022 02:00 am ET

SHAREHOLDER DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 22, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ:KRBP) for violations of the federal securities laws.

Aug 21, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Carvana, Kiromic, Tuya, and LifeStance and Encourages Investors to Contact the Firm

Aug 21, 2022 10:40 am ET

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – KRBP

Aug 20, 2022 10:02 am ET

KRBP CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Kiromic BioPharma, Inc. Shareholders of Securities Fraud Class Action Lawsuit

RADNOR, Pa., Aug. 20, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP). The action charges Kiromic with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Kiromic's materially misleading statements and omissions to the public, Kiromic investors have suffered significant losses.

Aug 19, 2022 09:45 pm ET

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 19, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ:KRBP) for violations of the federal securities laws.

Aug 19, 2022 09:15 am ET

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed against Kiromic BioPharma, Inc. (KRBP) and Encourages Investors with Significant Losses to Contact the Firm

The law firm of Kessler Topaz Meltzer & Check, LLP (

Aug 19, 2022 05:45 am ET

KRBP SHAREHOLDER ALERT: Jakubowitz Law Reminds Kiromic Shareholders of a Lead Plaintiff Deadline of October 4, 2022

NEW YORK, Aug. 19, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP).

Aug 18, 2022 05:27 pm ET

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Kiromic BioPharma, Inc.

Aug 18, 2022 11:00 am ET

Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kiromic BioPharma, Inc. (KRBP) Investors of Class Action and to Actively Participate

Aug 18, 2022 05:45 am ET

KRBP LAWSUIT ALERT: Levi & Korsinsky Notifies Kiromic BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Aug. 18, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) of a class action securities lawsuit.

Aug 17, 2022 09:35 pm ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 17, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ:KRBP) for violations of the federal securities laws.

Aug 17, 2022 06:37 pm ET

Kiromic Biopharma, Inc. Shareholder Notificaiton: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Kiromic Biopharma, Inc. (KRBP)

The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Kiromic Biopharma, Inc. (NASDAQ: KRBP) securities...

Aug 17, 2022 05:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Kiromic BioPharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 4, 2022 - (NASDAQ: KRBP)

NEW YORK, Aug. 17, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kiromic BioPharma, Inc..

Aug 16, 2022 04:48 pm ET

KRBP ALERT: Hagens Berman, National Trial Attorneys, Encourages Investors in Kiromic BioPharma (KRBP) with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed

Aug 16, 2022 02:53 pm ET

ROSEN, A TOP RANKED LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – KRBP

Aug 16, 2022 05:45 am ET

KRBP ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2022 in the Class Action Filed on Behalf of Kiromic BioPharma, Inc. Shareholders

NEW YORK, Aug. 16, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP) alleging that the Company violated federal securities laws.

Aug 15, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coinbase, Carvana, and Kiromic and Encourages Investors to Contact the Firm

Aug 15, 2022 07:45 pm ET

KRBP INVESTOR NEWS: ROSEN, A LEADING NATIONAL FIRM, Encourages Kiromic BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action -

NEW YORK, Aug. 15, 2022 /PRNewswire/ --

Aug 15, 2022 01:10 pm ET

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Kiromic BioPharma, Inc. (KRBP) with Significant Losses to Contact Firm's Attorneys, Securities Class Action Filed

SAN FRANCISCO, Aug. 15, 2022 /PRNewswire/ -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now.

Aug 15, 2022 05:45 am ET

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Kiromic Investors of a Lead Plaintiff Deadline of October 4, 2022

NEW YORK, Aug. 15, 2022 /PRNewswire/ -- Attention Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP) shareholders:

Aug 12, 2022 12:05 pm ET

Kiromic Biopharma, Inc. Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Kiromic Biopharma, Inc. (KRBP)

Aug 12, 2022 10:39 am ET

Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kiromic BioPharma, Inc. (KRBP) Investors of Class Action and to Actively Participate

Aug 12, 2022 05:45 am ET

KRBP SHAREHOLDER ALERT: Jakubowitz Law Reminds Kiromic Shareholders of a Lead Plaintiff Deadline of October 4, 2022

NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP).

Aug 10, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Carvana and Kiromic and Encourages Investors to Contact the Firm

Aug 10, 2022 05:51 pm ET

EQUITY ALERT: Rosen Law Firm Encourages Kiromic BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – KRBP

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Kiromic BioPharma, Inc. (NASDAQ: KRBP): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public offering conducted on or about July 2, 2021 (the “IPO”); and/or (ii) between June 25, 2021 and August 13, 2021, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than October 4, 2022.

Aug 10, 2022 04:31 pm ET

Kiromic BioPharma, Inc. Investors: Class action lawsuit filed on behalf of investors; Deadline October 4, 2022; the Portnoy Law Firm

The Portnoy Law Firm advises Kiromic BioPharma, Inc. (“Kiromic” or the “Company”) (NASDAQ: KRBP) investors that a class action filed on behalf of investors. Kiromic investors that lost money on their investment are encouraged to contact Lesley...

Aug 10, 2022 11:00 am ET

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 10, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ:KRBP) for violations of the federal securities laws.

Aug 10, 2022 10:00 am ET

Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kiromic BioPharma, Inc. (KRBP) Investors of Class Action and to Actively Participate

NEW YORK, Aug. 10, 2022 /PRNewswire/ -- Attorney Advertising Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) and certain of its officers, on behalf of a class consisting of all persons and entities that purchased or otherwise acquired Kiromic: (1) common stock pursuant and/or traceable to the Offering Documents (defined below) and/or (2) securities between June 25, 2021, and August 13, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged t

Aug 09, 2022 10:49 pm ET

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Kiromic Biopharma, Inc. (KRBP)

The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Kiromic Biopharma, Inc. (NASDAQ: KRBP) securities pursuant to the Company's July 2021 initial public offering ("IPO"), or between June 25, 2021 a

Aug 09, 2022 09:00 pm ET

KIROMIC ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Kiromic BioPharma, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Kiromic BioPharma, Inc. (“Kiromic” or the “Company”) (NASDAQ: KRBP) in the United States district Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Kiromic securities between June 25, 2021 and August 13, 2021, both dates inclusive, or pursuant to the Company’s July 2, 2021 IPO (the “Class Period”). Investors have until October 4, 2022 to apply to the Court to be appointed as lead plaint

Aug 09, 2022 07:23 pm ET

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Kiromic BioPharma, Inc. (KRBP) with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed

Aug 09, 2022 09:08 am ET

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. (“Kiromic” or “the Company”) (NASDAQ:

Aug 09, 2022 08:30 am ET

Gainey McKenna & Egleston Filed A Class Action Lawsuit Against Kiromic BioPharma, Inc. (KRBP)

Gainey McKenna & Egleston filed a class action lawsuit against Kiromic BioPharma, Inc. (“Kiromic” or the “Company”) (NASDAQ: KRBP) and against certain officers and directors of the Company. The class action was filed in the United States District...

Aug 08, 2022 06:40 pm ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. (“Kiromic” or “the Company”) (NASDAQ:

Aug 08, 2022 11:35 am ET

KRBP Class Action Complaint Filed: Johnson Fistel, Globally-Recognized Law Firm Encourages Shareholders to Submit Their Kiromic Losses

Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Kiromic BioPharma, Inc. (“Kiromic” or the “Company”) (NASDAQ: KRBP). The class action is on behalf of shareholders who...

Aug 05, 2022 11:30 pm ET

Gainey McKenna & Egleston Announces It Has Filed A Class Action Lawsuit Against Kiromic BioPharma, Inc. (KRBP)

Gainey McKenna & Egleston announces that it has filed a class action lawsuit against Kiromic BioPharma, Inc. (“Kiromic” or the “Company”) (NASDAQ: KRBP) and against certain officers and directors of the Company. The class action was filed in the...

Jul 12, 2022 08:18 am ET

Kiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific Officer

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces the appointment of Leonardo Mirandola, Ph.D., as Chief Scientific Officer, effective immediately. Dr. Mirandola has served as the Company’s Vice President of Research & Development and Clinical Translation since September 2021. His previous role was Head of Clinical Translation from 2020 to 2021,

Jul 07, 2022 08:18 am ET

Kiromic BioPharma Achieves Milestone with Timely Completion of Expanded cGMP Manufacturing Facility to Support Cell Therapy Oncology Pipeline

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces the timely completion of construction on its expanded current good manufacturing practice (cGMP) manufacturing facility in Houston. This significant milestone was accomplished within the timeline established by the Company, specifically June 30, 2022.

Jun 21, 2022 08:17 am ET

Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate

Kiromic BioPharma, Inc. (NASDAQ: KRBP), a clinical-stage biotherapeutics company using its proprietary DIAMOND AI® (artificial intelligence) and data mining platform to discover and develop cell therapies with a focus on immuno-oncology, announces a strategic pipeline shift to prioritize its allogeneic, non-engineered off-the-shelf product candidate, Deltacel/KB-GDT™.

Jun 07, 2022 10:31 am ET

BioMed Leaders KRBP, NMLSF, VERU, AIMLF Report Latest Advances in Vaccines, Novel Therapeutics for Oncology, and Autism and HealthTech AI

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Kiromic BioPharma (NASDAQ: KRBP), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Veru Inc. (NASDAQ:...

Jun 07, 2022 07:05 am ET

Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement

Kiromic BioPharma, Inc. (NASDAQ: KRBP), a clinical-stage biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and data mining platform to discover and develop cell and gene therapies with a focus on immuno-oncology, today announces it has entered into a sponsored research agreement (SRA) with Principal Investigator James W. Welsh, M.D. of The University of Texas MD Anderson Cancer Center.

May 13, 2022 08:08 am ET

Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

May 11, 2022 06:58 am ET

Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces the Company will submit an amended Investigational New Drug Application (IND) for its first oncology cell therapy candidate Procel™ directly to the FDA in the second half of 2022.

Apr 13, 2022 03:28 pm ET

Lifshitz Law PLLC Announces Investigations of Bumble Inc. (NASDAQ: BMBL), Kiromic BioPharma, Inc. (NASDAQ: KRBP), FirstCash Holdings, Inc. (NASDAQ: FCFS), and QuantumScape Corporation (NYSE: QS)

Bumble Inc. (NASDAQ: BMBL) Lifshitz Law PLLC announces that a class action complaint has been filed against BMBL alleging that, BMBL failed to disclose that: (i) Bumble’s paying user growth trends had abruptly reversed in 3Q21 and Bumble had...

Apr 11, 2022 04:03 pm ET

Kiromic BioPharma Announces Availability of Company’s Current Corporate Presentation

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND AI® (artificial intelligence) and big data mining platform to discover, validate and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces the availability of the Company’s most recent corporate presentation. The updated presentation can be accessed on the investor relations section of the Company’s website. The corporate presentation was also filed as a Form 8-K with the Secu

Apr 08, 2022 04:07 pm ET

Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Highlights

Apr 04, 2022 02:48 pm ET

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Kiromic BioPharma, Inc. (KRBP) with Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violatio

Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now. The firm is investigating Kiromic’s possible securities law violations. Visit:...

Apr 03, 2022 06:46 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma, Inc. - KRBP

NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Apr 01, 2022 07:07 am ET

Kiromic Biopharma Announces Filing of Form 12b-25

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases, today announces that it has filed a Form 12b-25 with the SEC to obtain a 15-calendar day extension to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Form 10-K”). The Company expects to file its 2021 Form

Mar 30, 2022 10:01 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma, Inc. - KRBP

Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma, Inc. (“Kiromic” or the “Company”) (NASDAQ: KRBP). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....

Mar 28, 2022 01:08 pm ET

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Kiromic BioPharma, Inc. (KRBP) with Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violatio

Mar 22, 2022 01:02 pm ET

HAGENS BERMAN, NATION TRIAL ATTORNEYS, Encourages Investors in Kiromic BioPharma, Inc. (KRBP) with Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations

Mar 21, 2022 08:57 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma, Inc. - KRBP

Mar 16, 2022 08:57 pm ET

HAGENS BERMAN, NATION TRIAL ATTORNEYS, Encourages Investors in Kiromic BioPharma, Inc. (KRBP) with Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations

Mar 11, 2022 04:02 pm ET

Kiromic BioPharma Provides Business Update and Reports Third Quarter 2021 Financial Results

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases, today reported business updates and financial results for its third quarter ending September 30, 2021.

Feb 03, 2022 08:58 am ET

Kiromic BioPharma Announces Changes in Management, Board of Directors

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases, today announces changes in management, and in the Company’s Board of Directors. In addition, the Company announces the formation of a Disclosure Committee.

Feb 03, 2022 08:02 am ET

Kiromic BioPharma Appoints Frank Tirelli and Dr. Karen Reeves to Company’s Board of Directors

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases, today announces the appointment of two outside directors to the Company’s Board of Directors: Frank Tirelli and Karen Reeves, M.D.

Nov 24, 2021 04:12 pm ET

Kiromic BioPharma Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases, today announced that it received a written notice (the “Notice”) on November 18, 2021 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listi

Oct 25, 2021 07:03 am ET

Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01, Company’s Phase 1 Cell Therapy Cancer V

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases, today announces the results of a published pilot Phase 1 clinical trial that showed KiroVax/BSK01, Kiromic’s cell therapy cancer vaccine candidate, in combination with chemotherapy, demonstrated a significant progression free survival (PFS) benefit in one of the pati

Oct 11, 2021 08:02 am ET

Kiromic BioPharma Announces Strategic Collaboration with Gemelli Teaching Hospital to Accelerate the Analysis of Allogeneic CAR-T Clinical Trial Candidate Alexis ISO-1 in Solid Cancers

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a pre-clinical stage biotechnology company using its proprietary DIAMOND® artificial intelligence (AI) platform to improve drug discovery and development with a therapeutic focus on immuno-oncology, announces it has engaged in a strategic collaboration with Gemelli Teaching Hospital IRCCS to accelerate the analysis of the Company’s first allogeneic CAR-T clinical trial candidate Alexis ISO-1.

Oct 05, 2021 10:13 pm ET

Kiromic BioPharma Announces Chief Financial Officer Transition

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a pre-clinical stage biotechnology company using its proprietary DIAMOND® artificial intelligence (“A.I.”) platform to improve drug discovery and development with a therapeutic focus on immune-oncology, announces it has appointed Daniel Clark as interim Chief Financial Officer (“CFO”), effective as of September 30, 2021.

Aug 13, 2021 03:32 pm ET

Kiromic BioPharma Reports Second Quarter 2021 Financial Results and Operating Highlights

Kiromic Operating Highlights of 2Q-2021

Jul 29, 2021 02:44 pm ET

Kiroma BioPharma, Inc. Investors: Company Investigated by the Portnoy Law Firm

The Portnoy Law Firm advises Kiroma BioPharma, Inc. ("Kiroma" or the "Company") (NASDAQ: KRBP) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors...

Jul 28, 2021 08:49 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma, Inc. - KRBP

NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Jul 26, 2021 08:16 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma, Inc. - KRBP

Jul 26, 2021 06:55 pm ET

Kiromic Announces the Acquisition of InSilico Solutions Leveraging on Bioinformatics and Artificial Intelligence to Advance Clinical Development on Its Outpatient Allogeneic CAR-T for Solid Tumors

Kiromic Biopharma, Inc. (Nasdaq: KRBP), a pioneer in immuno oncology cellular therapy in solid tumors, is pleased to announce it has completed the acquisition of InSilico Solutions.

Jul 21, 2021 01:20 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma, Inc. - KRBP

NEW YORK, July 21, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Jul 16, 2021 02:53 pm ET

Kiromic BioPharma Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid Tumors

Kiromic BioPharma, Inc. (Nasdaq: KRBP)

Jul 02, 2021 04:23 pm ET

Kiromic BioPharma, Inc. Announces Closing of Public Offering

Kiromic BioPharma, Inc. (Nasdaq: KRBP) (the “Company”), an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $5.00 per share, resulting in gross proceeds to the Company of $40 million. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,200,000 shares

Jun 29, 2021 06:59 pm ET

Kiromic BioPharma, Inc. Announces Pricing of Public Offering

Kiromic BioPharma, Inc. (Nasdaq: KRBP) (the “Company”), an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $40 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. In addition, the Company has granted the under

Jun 28, 2021 07:01 am ET

KRBP Presenting at 2021 Next-Gen Immuno Oncology Congress Showcasing Its Proprietary AI Targets for Off-the-Shelf Allogenic CAR-T for Solid Tumors

Kiromic Biopharma, Inc. (Nasdaq: KRBP)

Jun 17, 2021 07:49 am ET

KRBP Presenting at July 2021 Gamma Delta T Cell Summit to Showcase Our Off-The-Shelf Allogeneic Gamma Delta T Cell Therapy

Kiromic is being recognized as a pioneer of Gamma Delta T (GDT) cell therapy manufacturing and has been invited to present its off-the-shelf allogeneic CAR-T technology at the prestigious Gamma Delta T Cell Summit in July 2021.

Jun 07, 2021 08:07 am ET

Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Núñez as Chief Operating and Manufacturing Officer

Kiromic BioPharma, Inc. (Nasdaq: KRBP)

May 24, 2021 07:55 am ET

Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter

Kiromic Biopharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics, today announced the submission of a novel Investigational New Drug (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial that has the potential to be a universal CAR T-Cell therapy for any solid malignancy that expresses the biomarker Iso-mesothelin, with higher efficacy, higher safety, as well as lower manufacturing and distribution co

May 21, 2021 07:59 am ET

Kiromic Announces Identification of Novel Targets for Allogeneic CAR Gamma Delta T-cell Therapy in Solid Tumors Utilizing Kiromic’s Proprietary Artificial Intelligence Engine

Kiromic Biopharma, Inc. (Nasdaq: KRBP) is an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics.

May 17, 2021 07:58 am ET

Kiromic Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor - Gamma Delta T-cell Therapy

Kiromic Biopharma, Inc. (Nasdaq: KRBP)

May 14, 2021 12:50 pm ET

Kiromic BioPharma Reports First Quarter 2021 Financial Results and Continued Corporate Progress

Kiromic BioPharma (NASDAQ: KRBP), a pre-clinical stage biotechnology company using its proprietary DIAMOND® artificial intelligence (“A.I.”) platform to improve drug discovery and development with a therapeutic focus on immune-oncology, today announced its quarterly results for the three months ended March 31, 2021, and provided an update on its corporate developments.

May 03, 2021 08:36 am ET

Kiromic Announces 6 Posters Presented at American Association of Cancer Research 2021 Showcasing our Artificial Intelligence (AI) Biomarker Engine

Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics, has announced its technology showcases at the recent American Association of Cancer Research (“AACR”) 2021 meeting.

Mar 31, 2021 12:32 pm ET

Kiromic BioPharma Reports Fiscal Year 2020 Financial Results and Continued Corporate Progress

Kiromic BioPharma (NASDAQ: KRBP), a pre-clinical stage biotechnology company using its proprietary DIAMOND® artificial intelligence (“A.I.”) platform to improve drug discovery and development with a therapeutic focus on immune-oncology, today announced its financial results for the year ended December 31, 2020, and provided an update on its corporate developments.

Mar 26, 2021 09:53 am ET

Kiromic BioPharma, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

Kiromic BioPharma, Inc. (Nasdaq: KRBP) is an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics.

Mar 09, 2021 05:04 pm ET

Kiromic to Resubmit Two Expanded INDs to the FDA for Its Allogenic, Off-the-Shelf Gamma-Delta T cell Therapies for Multiple Solid Tumors

Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology, announced today the planned resubmission of two investigational new drug (IND) applications with the U.S. Food and Drug Administration (FDA).

Jan 26, 2021 04:31 pm ET

Kiromic Announces License Agreement With Longwood University for chPD1

Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics, has announced the completion of the chPD1 licensing agreement with Longwood University.

Jan 19, 2021 08:53 pm ET

Kiromic Announces the Completion of its GMP Manufacturing Facility in Houston, Texas, to Support the Manufacturing of the First In-Human Allogenic CAR-T Trial

Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics, has announced the completion and certification of its GMP facility in Houston, Texas:

Jan 04, 2021 08:35 pm ET

Kiromic Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target

Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and proprietary neural network platform with a therapeutic focus on immuno-oncology, announces the filing of key European patents for its chimeric PD-1 (chPD1) target.

Dec 17, 2020 12:45 pm ET

Kiromic Announces Submission of Two IND Applications for PD1 Gamma-delta CAR - T cell Therapy with the FDA

Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology, announced today the submission of two investigational new drug (IND) applications with the U.S. Food and Drug Administration (FDA) for the initiation of:

Nov 30, 2020 04:51 pm ET

Kiromic BioPharma Reports Third Quarter 2020 Financial Results and Continued Corporate Progress

Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a pre-clinical stage biotechnology company using its proprietary DIAMOND® artificial intelligence (“A.I.”) platform to improve drug discovery and development with a therapeutic focus on immune-oncology, today announced its financial results for the third quarter ended September 30, 2020, and provided an update on its corporate developments.

Oct 20, 2020 04:15 pm ET

Kiromic BioPharma Announces Closing of Initial Public Offering

Kiromic BioPharma, Inc. (the “Company”), a target discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology, today announced the closing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $12.00 per share, for gross proceeds of $15,000,000, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 shares of common stock at

Oct 15, 2020 05:46 pm ET

Kiromic BioPharma Announces Pricing of Initial Public Offering

Kiromic BioPharma, Inc. (the “Company”), a target discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology, today announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $12.00 per share, for gross proceeds of $15,000,000, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 shares of common stock at

You are here

Kiromic Biopharma Inc (PK:KRBP)

Business Focus: Bio Therapeutic Drugs